Table 1.
Patient and treatment characteristics (N=22,156).
| All Patients (N=22156) | Axillary Surgery | P-Value | ||
|---|---|---|---|---|
| ALND (10+ LNs) (N=19966) | SLNB (1–5 LNs) (N=2190) | |||
| Age (Years) | <0.001 | |||
| ≤50 | 7814 (35.3%) | 6948 (34.8%) | 866 (39.5%) | |
| >50 | 14342 (64.7%) | 13018 (65.2%) | 1324 (60.5%) | |
| Median (IQR) | 56 (47 – 66) | 56 (47 – 66) | 54 (45 – 63) | <0.001 |
| Race | 0.002 | |||
| White | 17369 (78.4%) | 15713 (78.7%) | 1656 (75.6%) | |
| Black | 3628 (16.4%) | 3212 (16.1%) | 416 (19%) | |
| Other | 919 (4.1%) | 823 (4.1%) | 96 (4.4%) | |
| Charlson/Deyo Comorbidity Score | 0.001 | |||
| 0 | 18744 (84.6%) | 16832 (84.3%) | 1912 (87.3%) | |
| 1 | 2813 (12.7%) | 2584 (12.9%) | 229 (10.5%) | |
| ≥2 | 599 (2.7%) | 550 (2.8%) | 49 (2.2%) | |
| Facility Type | 0.003 | |||
| Academic | 6613 (29.8%) | 5969 (29.9%) | 644 (29.4%) | |
| Integrated Network | 1519 (6.9%) | 1344 (6.7%) | 175 (8%) | |
| Comprehensive | 10950 (49.4%) | 9835 (49.3%) | 1115 (50.9%) | |
| Community | 3072 (13.9%) | 2816 (14.1%) | 256 (11.7%) | |
| ER Status | <0.001 | |||
| Positive | 11942 (53.9%) | 10987 (55%) | 955 (43.6%) | |
| Negative | 9592 (43.3%) | 8412 (42.1%) | 1180 (53.9%) | |
| PR Status | <0.001 | |||
| Positive | 14552 (65.7%) | 13334 (66.8%) | 1218 (55.6%) | |
| Negative | 7065 (31.9%) | 6142 (30.8%) | 923 (42.1%) | |
| HER2 Status* | <0.001 | |||
| Positive | 2574 (11.6%) | 2210 (11.1%) | 364 (16.6%) | |
| Negative | 8132 (36.7%) | 7261 (36.4%) | 871 (39.8%) | |
| Grade | <0.001 | |||
| 1 | 1334 (6%) | 1237 (6.2%) | 97 (4.4%) | |
| 2 | 7235 (32.7%) | 6655 (33.3%) | 580 (26.5%) | |
| 3 | 12141 (54.8%) | 10805 (54.1%) | 1336 (61%) | |
| Histology | <0.001 | |||
| Invasive Ductal | 19265 (87%) | 17283 (86.6%) | 1982 (90.5%) | |
| Invasive Lobular | 2502 (11.3%) | 2343 (11.7%) | 159 (7.3%) | |
| Other Invasive | 389 (1.8%) | 340 (1.7%) | 49 (2.2%) | |
| Clinical N Stage | 0.005 | |||
| 2 | 15180 (68.5%) | 13621 (68.2%) | 1559 (71.2%) | |
| 3 | 6976 (31.5%) | 6345 (31.8%) | 631 (28.8%) | |
| Clinical T Stage | 0.05 | |||
| 1 | 4526 (20.4%) | 4114 (20.6%) | 412 (18.8%) | |
| 2 | 11886 (53.6%) | 10714 (53.7%) | 1172 (53.5%) | |
| 3 | 5744 (25.9%) | 5138 (25.7%) | 606 (27.7%) | |
| Surgery Type | <0.001 | |||
| Lumpectomy | 5983 (27%) | 5194 (26%) | 789 (36%) | |
| Mastectomy | 16173 (73%) | 14772 (74%) | 1401 (64%) | |
| Treated with Chemotherapy | 19135 (86.4%) | 17216 (86.2%) | 1919 (87.6%) | 0.21 |
| Chemotherapy Type** | <0.001 | |||
| Adjuvant | 10223 (53.4%) | 9778 (56.8%) | 445 (23.2%) | |
| Neoadjuvant | 7596 (39.7%) | 6231 (36.2%) | 1365 (71.1%) | |
| Treated with Radiation | 16400 (74%) | 14845 (74.4%) | 1555 (71%) | <0.001 |
| Surgery and Radiation Combination | ||||
| Lumpectomy + Radiation | 5003 (22.6%) | 4636 (21.9%) | 640 (29.2%) | <0.001 |
| Lumpectomy + No Radiation | 920 (4.2%) | 776 (3.9%) | 144 (6.6%) | |
| Mastectomy + Radiation | 11397 (51.4%) | 10482 (52.5%) | 915 (41.8%) | P<.001 |
| Mastectomy + No Radiation | 4574 (20.6%) | 4105 (20.6%) | 469 (21.4%) | |
| Treated with Endocrine Therapy | ||||
| Of All Patients | 12053 (54.4%) | 11053 (55.4%) | 1000 (45.7%) | <0.001 |
| Of ER+ or PR+ Patients | 11644 (78%) | 10686 (78.2%) | 958 (75.7%) | 0.02 |
| Number of LNs Examined - Median (IQR) | 16 (12 – 21) | 17 (13 – 21) | 3 (2 – 4) | <0.001 |
| Number of Positive LNs - Median (IQR) | 6 (3 – 10) | 6 (4 – 11) | 1 (0 – 3) | <0.001 |
*
HER2-status is frequently missing in this database due to the fact that it was only reliably collected starting in 2010.
**
Chemotherapy Type is out of all patients who had chemotherapy.